Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT) today and set a price target of $91. The company’s shares opened today at $48.80.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.1% and a 34.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $88.63 average price target, implying an 81.6% upside from current levels. In a report issued on January 30, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.05 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 1.16M.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
